BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pae CU, Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Serretti A, Emsley R. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol 2017;32:235-48. [PMID: 28430670 DOI: 10.1097/YIC.0000000000000177] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Stip E, Abdel-Baki A, Roy MA, Bloom D, Grignon S. [Long-acting antipsychotics: The QAAPAPLE algorithm review]. Can J Psychiatry 2019;64:697-707. [PMID: 31088133 DOI: 10.1177/0706743719847193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, De Filippis S. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat 2018;14:1645-56. [PMID: 29950846 DOI: 10.2147/NDT.S171002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry 2019;19:114. [PMID: 30991969 DOI: 10.1186/s12888-019-2103-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
4 Singh A, Gopal S, Kim E, Mathews M, Kern-Sliwa J, Turkoz I, Wooller A, Berlin J. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. Int Clin Psychopharmacol 2018;33:213-6. [PMID: 29494348 DOI: 10.1097/YIC.0000000000000215] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat 2019;15:183-98. [PMID: 30662264 DOI: 10.2147/NDT.S189245] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
6 Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clin Psychopharmacol Neurosci 2021;19:233-42. [PMID: 33888652 DOI: 10.9758/cpn.2021.19.2.233] [Reference Citation Analysis]
7 Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not? Clin Psychopharmacol Neurosci 2021;19:434-48. [PMID: 34294613 DOI: 10.9758/cpn.2021.19.3.434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Stone JM, Roux S, Taylor D, Morrison PD. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse. Ther Adv Psychopharmacol 2018;8:333-6. [PMID: 30524701 DOI: 10.1177/2045125318795130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mason K, Barnett J, Pappa S. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. Ther Adv Psychopharmacol 2021;11:20451253211029490. [PMID: 34349980 DOI: 10.1177/20451253211029490] [Reference Citation Analysis]
10 Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clin Psychopharmacol Neurosci 2020;18:153-8. [PMID: 31958916 DOI: 10.9758/cpn.2020.18.1.153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]